Patents Examined by Deepak R. Rao
  • Patent number: 10253007
    Abstract: The present invention provides taxanes compounds with a formula (I) or formula (II) structure, a method for preparing the compounds, as well as the use of the compositions containing the compounds, pharmaceutically acceptable salts and solvates thereof as active ingredients in manufacturing oral antitumor medicaments, In formula (I), R1 is —COR6, —COOR6 or —CONR7aR7b; R2 is a C1-C6 alkyl, a C1-C6 alkenyl, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; R3 is —OR6, —OCOOR6, —OCOSR6 or —OCONR7aR7b; R4 is —OR6, —OCOOR6, —OCOSR6, —OCONR7aR7b or H; wherein, R6 is a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; R7a and R7b are respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 9, 2019
    Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
    Inventors: Wei Zhou, Yunrong Jing, Yongfeng Wang, Guocheng Wang
  • Patent number: 10246423
    Abstract: The present invention relates to a process for preparing a statin precursor, which process comprises a first reaction step, wherein a hydroxy-pyrimidine-carbonitrile is reacted with an organic sulfonyl halide to form the sulfonate-pyrimidine-carbonitrile; a second reaction step, wherein the sulfonate-pyrimidine-carbonitrile is reacted with N-methylmethane sulfonamide to form a pyrimidinyl-sulfonamide; and optionally a third reaction step, wherein the pyrimidinyl-sulfonamide is reacted with a reducing agent. All steps are conducted in toluene as the main solvent.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: April 2, 2019
    Assignee: Centrient Pharmaceuticals Netherlands B.V.
    Inventors: Ben De Lange, Karin Henderika Maria Bessembinder, Dennis Heemskerk
  • Patent number: 10245262
    Abstract: The present invention provides ligands which bind to MR1, some of which induce MR1 to bind to MAIT cells thereby activating or inhibiting MAIT cell activation.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: April 2, 2019
    Assignees: The University of Queensland, Monash University, The University of Melbourne
    Inventors: Alexandra Jane Corbett, James McCluskey, Lars Kjer-Nielsen, Zhenjun Chen, Jamie Rossjohn, Onisha Patel, Richard William Birkinshaw, Sidonia Barbara Guiomar Eckle, David Paul Fairlie, Ligong Liu, Jeffrey Yam Wing Mak
  • Patent number: 10246463
    Abstract: Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF-1 ? subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: April 2, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kirk R. Gustafson, Martin J. Schnermann, Susanna T. S. Chan, Paresma R. Patel, William D. Figg, James B. McMahon
  • Patent number: 10245261
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 2, 2019
    Assignee: NantBio, Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
  • Patent number: 10239879
    Abstract: According to the present invention, differently from well-known production methods, with the use of a different starting material, Ullmann condensation which may decrease the yield with an increase of a production scale can be avoided and thus 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one can be provided safely and stably with high reaction yield.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: March 26, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryo Suzuki, Atsushi Hiramatsu, Motoaki Tateyama, Hideyuki Sasahara
  • Patent number: 10239878
    Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 26, 2019
    Assignee: LUMIPHORE, INC.
    Inventors: David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
  • Patent number: 10239838
    Abstract: The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • Patent number: 10233194
    Abstract: The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH2, and optionally comprising a pharmaceutically acceptable salt, hydrate, or solvate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: March 19, 2019
    Assignee: Duquesne Unversity of the Holy Spirit
    Inventor: Aleem Gangjee
  • Patent number: 10233157
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: March 19, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
  • Patent number: 10227333
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: March 12, 2019
    Assignee: CURTANA PHARMACEUTICALS, INC.
    Inventors: Graham Beaton, Fabio Tucci, Satheesh B. Ravula, Hua-Yu Wang
  • Patent number: 10226464
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 12, 2019
    Assignee: ImmuneTarget, Inc.
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Patent number: 10226467
    Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 12, 2019
    Assignees: Universitat de Valencia, Institut Quimic de Sarria Cets Fundacio Privada, Institut Univ. de Ciencia I Tecnologia, S.A.
    Inventors: Ruben Artero Allepuz, Josep Castells Boliart, José Ignacio Borrell Bilbao, Beatriz Llamusi Troísi, Ariadna Bargiela Schönbrunn, Piotr Konieczny, Marta Pascual Gilabert, Jordi Teixidó Closa, Roger Estrada Tejedor, Alejandro López González
  • Patent number: 10226446
    Abstract: The present invention relates to an FK506 derivative which has reduced immunosuppressive activity but maintains nerve regeneration activity, a preparing method thereof, and a pharmaceutical composition comprising the same for preventing or treating nervous system diseases. A composition comprising 9-deoxo-prolyl-FK506, 31-O-demethyl-FK506, or 9-deoxo-31-O-demethyl-FK506 can promote nerve regeneration and has reduced immunosuppressive activity, thereby reducing side effects in the treatment of nervous system diseases.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: March 12, 2019
    Assignee: INTRON BIOTECHNOLOGY CO., LTD
    Inventors: Yeo Joon Yoon, Ho Jeong Kwon, Yeon Hee Ban, Shinde Pramodb
  • Patent number: 10227296
    Abstract: The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for the treatment and/or prevention of a disease, disorder or condition in which modulation of microsomal prostaglandin E synthase-1 activity is beneficial, such as pain, inflammation and cancer.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: March 12, 2019
    Assignee: Arcturum Real Estate AB
    Inventors: Peter Söderman, Mats A. Svensson, Annika Kers, Liselott Öhberg, Katharina Högdin, Andreas Hettman, Jesper Hallberg, Maria Ek, Johan Bylund, Johan Nord
  • Patent number: 10221162
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 5, 2019
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • Patent number: 10221177
    Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: March 5, 2019
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Xinyuan Wu
  • Patent number: 10221196
    Abstract: Described herein are crystalline forms of a compound of formula (II?), including toluene solvates off A TD-CLE, as well as processes for the preparation thereof and use thereof in the preparation of cephalosporin compounds such as ceftolozane. Provided herein is a crystalline form of a compound of formula (II?): wherein X is CI, Br, or I; and R1 and R2 are each independently an oxygen protecting group; processes for making the crystalline form, and use of said form in the synthesis of antibacterial cephalosporins such as ceftolozane.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas, Giovanni Fogliato, Manuel Scanu, You Seok Hwang
  • Patent number: 10214520
    Abstract: The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the ? opioid receptor and/or the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: February 26, 2019
    Assignee: GRUENENTHAL GMBH
    Inventors: Anita Wegert, Sven Kuehnert, Rene Michael Koenigs, Bert Nolte, Klaus Linz, Stephanie Harlfinger, Babette-Yvonne Koegel, Paul Ratcliffe, Fritz Theil, Olga Groeger, Birgit Braun
  • Patent number: 10214543
    Abstract: Described herein are methods for the manufacture of ceftolozane and related compounds, as well as compositions comprising the same.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas, Giovanni Fogliato, Manuel Scanu, Michele Benotti